The overarching goal of the Immunology Program is to define the basic mechanisms that control immunity in order to develop and optimize immunotherapies that generate a specific and durable anti-tumor immune response. To achieve this goal, we have strong research themes in place focused on the following Aims: 1) To elucidate the mechanisms that control immune tolerance, 2) To understand the development and maintenance of immunological memory, and 3) To develop and optimize cancer immunotherapies. The Immunology Program is led by Yoji Shimizu, PhD, and new co-leader, Jeffrey Miller, MD. Drs. Shimizu and Miller work collaboratively to accelerate Immunology Program research findings through the translational pipeline. Dr. Shimizu works with Immunology Program members to move high-impact and innovative basic research advances into cancer-relevant models and preclinical studies, and Dr. Miller bridges the basic science discoveries to resources within the Masonic Cancer Center in order to ultimately translate Immunology Program research findings into phase 1 clinical trials. The Program has 22 members, representing 9 departments and 3 schools or colleges (Medical School, College of Science and Engineering, and College of Veterinary Medicine). For the last budget year, these members were supported by $2.5 million in direct costs from the National Cancer Institute; funding from all peer-reviewed sources totaled $7.6 million in direct costs. Since 2013, Program members have published 354 papers (21% in journals with an impact factor >10), 24% of which resulted from intraprogrammatic collaborations, 23% from interprogrammatic collaborations, and 80% from external collaborations. Since 2013, 74 clinical trials in all clinical research categories have opened under this programmatic area and have accrued 203 patients. Access to Masonic Cancer Center Shared Resources, particularly Flow Cytometry and Translational Cell Therapy, is essential to the success of the Immunology Program. The Masonic Cancer Center has also enhanced Program activities through new faculty recruitments and funding of 4 pilot projects that resulted in 3 NCI-funded grants and a total ROI of $4.5M. The MCC supported and funded 21 monthly seminars that included 5 invited external speakers. Extensive intraprogrammatic and interprogrammatic interactions are enhanced by regular research-in-progress supergroup meetings, a faculty-only data club, a journal club, and an annual retreat sponsored by the Masonic Cancer Center. Program members also play a leadership role in training the next generation of cancer researchers. The Immunology Program research is aligned with the Masonic Cancer Center's strategic Scientific Priority for Growth (SPG1) to expand recent discoveries in immunotherapy and cellular therapeutics to include solid tumors. Furthermore, the Program's research addresses the elevated rates of myeloid leukemia and melanoma in Minnesota as well as developing novel therapies to reduce cancer morbidity and mortality for the major cancer burdens in MN: prostate, breast, lung.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-22
Application #
9859370
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
22
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Mondragon-Gonzalez, Ricardo; Perlingeiro, Rita C R (2018) Recapitulating muscle disease phenotypes with myotonic dystrophy 1 induced pluripotent stem cells: a tool for disease modeling and drug discovery. Dis Model Mech 11:
Kim, J-H; Frantz, A M; Sarver, A L et al. (2018) Modulation of fatty acid metabolism and immune suppression are features of in vitro tumour sphere formation in ontogenetically distinct dog cancers. Vet Comp Oncol 16:E176-E184
Jin, Jin; Zhang, Lin; Leng, Ethan et al. (2018) Detection of prostate cancer with multiparametric MRI utilizing the anatomic structure of the prostate. Stat Med 37:3214-3229
Pierpont, Elizabeth I; Hudock, Rebekah L; Foy, Allison M et al. (2018) Social skills in children with RASopathies: a comparison of Noonan syndrome and neurofibromatosis type 1. J Neurodev Disord 10:21
Carlson, Erik S; Upadhyaya, Pramod; Villalta, Peter W et al. (2018) Analysis and Identification of 2'-Deoxyadenosine-Derived Adducts in Lung and Liver DNA of F-344 Rats Treated with the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone and Enantiomers of its Metabolite 4-(Methylnitrosamino)-1-(3-p Chem Res Toxicol 31:358-370
Lin, Lifeng; Chu, Haitao; Murad, Mohammad Hassan et al. (2018) Empirical Comparison of Publication Bias Tests in Meta-Analysis. J Gen Intern Med 33:1260-1267
Rashidi, Armin; Ebadi, Maryam; Said, Bassil et al. (2018) Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol :
Bejanyan, Nelli; Brunstein, Claudio G; Cao, Qing et al. (2018) Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv 2:909-922
Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494
Hupp, Meghan; Williams, Sarah; Dunnette, Brian et al. (2018) Comparison of evaluation techniques, including digital image analysis, for MYC protein expression by immunohistochemical stain in aggressive B-cell lymphomas. Hum Pathol :

Showing the most recent 10 out of 1013 publications